Offer - Urjas Oil for just ₹ 1 X
Nexovas O Tablet, a prescription drug, is manufactured in various forms such as Tablet. Other than this, Nexovas O Tablet has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Nexovas O Tablet is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
The most common side effects of Nexovas O Tablet are Upper respiratory tract infection. Apart from the aforementioned side effects, Nexovas O Tablet can also lead to other problems, which have been listed below. Normally, these side effects of Nexovas O Tablet are not long lasting and go away when the treatment is finished. If, however, they worsen or do not go away, please speak with your physician.
In addition, Nexovas O Tablet's effect is Unknown during pregnancy and Unknown for lactating mothers. Further, the section on Nexovas O Tablet related warnings talks about Nexovas O Tablet's effects on the liver, heart and kidney.
Nexovas O Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Nexovas O Tablet in conditions like Bradycardia (Slow Heart Rate), Low Blood Pressure (Hypotension), Low Blood Pressure (Hypotension). Other contraindications of Nexovas O Tablet have been discussed in the sections ahead.
Drug reaction of Nexovas O Tablet with other medicines has been reported. A complete list of these interactions is given below.
You should also be aware that Nexovas O Tablet is safe while driving, and is addiction.
Nexovas O Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Nexovas O Tablet safe for pregnant women?
Side effects of Nexovas O during pregnancy are not known because scientific research on this topic hasn't been done.
Is the use of Nexovas O Tablet safe during breastfeeding?
No research work has been carried out till date on effect of Nexovas O on breastfeeding women. So it is not known whether taking Nexovas O will cause side effects or not.
What is the effect of Nexovas O Tablet on the Kidneys?
Very few cases of side effects of Nexovas O on kidney have been reported.
What is the effect of Nexovas O Tablet on the Liver?
Side effects of Nexovas O rarely affect the liver.
What is the effect of Nexovas O Tablet on the Heart?
The heart can be affected by Nexovas O. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart the medicine only after medical advice.
Nexovas O Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Nexovas O Tablet unless your doctor advises you to do so -
Is this Nexovas O Tablet habit forming or addictive?
Nexovas O Tablet does not cause addiction.
Interaction between Food and Nexovas O Tablet
It is safe to take Nexovas O Tablet with food.
Interaction between Alcohol and Nexovas O Tablet
Due to lack of research, nothing can be said about side effects of consuming alcohol while taking Nexovas O Tablet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Benicar (olmesartan medoxomil)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173